Purpose of Study:
To evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).Study Dates:
July 7, 2020 - May 14, 2024
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Actelion Pharmaceuticals Ltd*
Sponsors:
Janssen Pharmaceutical Company of Johnson & JohnsonClinicalTrails.gov Identifier:
NCT04271475